BIOLASE INC (BIOL) Fundamental Analysis & Valuation

NASDAQ:BIOL • US0909117022

Current stock price

0.129 USD
-0.02 (-13.19%)
At close:
0.109 USD
-0.02 (-15.5%)
After Hours:

This BIOL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BIOL Profitability Analysis

1.1 Basic Checks

  • BIOL had negative earnings in the past year.
  • In the past year BIOL has reported a negative cash flow from operations.
  • BIOL had negative earnings in each of the past 5 years.
  • In the past 5 years BIOL always reported negative operating cash flow.
BIOL Yearly Net Income VS EBIT VS OCF VS FCFBIOL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • The Return On Assets of BIOL (-111.37%) is worse than 84.04% of its industry peers.
  • Looking at the Return On Equity, with a value of -14222.30%, BIOL is doing worse than 91.49% of the companies in the same industry.
Industry RankSector Rank
ROA -111.37%
ROE -14222.3%
ROIC N/A
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
BIOL Yearly ROA, ROE, ROICBIOL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

1.3 Margins

  • Looking at the Gross Margin, with a value of 34.26%, BIOL is doing worse than 69.68% of the companies in the same industry.
  • BIOL's Gross Margin has been stable in the last couple of years.
  • BIOL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
BIOL Yearly Profit, Operating, Gross MarginsBIOL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. BIOL Health Analysis

2.1 Basic Checks

  • BIOL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BIOL has been increased compared to 1 year ago.
  • Compared to 1 year ago, BIOL has a worse debt to assets ratio.
BIOL Yearly Shares OutstandingBIOL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
BIOL Yearly Total Debt VS Total AssetsBIOL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -13.20, we must say that BIOL is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BIOL (-13.20) is worse than 83.51% of its industry peers.
  • BIOL has a Debt/Equity ratio of 41.66. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 41.66, BIOL is doing worse than 91.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 41.66
Debt/FCF N/A
Altman-Z -13.2
ROIC/WACCN/A
WACC12.07%
BIOL Yearly LT Debt VS Equity VS FCFBIOL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M -30M

2.3 Liquidity

  • BIOL has a Current Ratio of 1.17. This is a normal value and indicates that BIOL is financially healthy and should not expect problems in meeting its short term obligations.
  • BIOL has a Current ratio of 1.17. This is amonst the worse of the industry: BIOL underperforms 89.89% of its industry peers.
  • BIOL has a Quick Ratio of 1.17. This is a bad value and indicates that BIOL is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BIOL's Quick ratio of 0.64 is on the low side compared to the rest of the industry. BIOL is outperformed by 95.74% of its industry peers.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.64
BIOL Yearly Current Assets VS Current LiabilitesBIOL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIOL Growth Analysis

3.1 Past

  • BIOL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.89%, which is quite impressive.
  • BIOL shows a small growth in Revenue. In the last year, the Revenue has grown by 0.13%.
  • The Revenue has been growing slightly by 1.27% on average over the past years.
EPS 1Y (TTM)95.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
Revenue 1Y (TTM)0.13%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Sales Q2Q%-3.21%

3.2 Future

  • BIOL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.31% yearly.
  • The Revenue is expected to grow by 5.36% on average over the next years.
EPS Next Y98.59%
EPS Next 2Y41.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.98%
Revenue Next 2Y5.36%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIOL Yearly Revenue VS EstimatesBIOL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
BIOL Yearly EPS VS EstimatesBIOL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. BIOL Valuation Analysis

4.1 Price/Earnings Ratio

  • BIOL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BIOL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIOL Price Earnings VS Forward Price EarningsBIOL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIOL Per share dataBIOL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

  • BIOL's earnings are expected to grow with 41.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.31%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIOL Dividend Analysis

5.1 Amount

  • No dividends for BIOL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOL Fundamentals: All Metrics, Ratios and Statistics

BIOLASE INC

NASDAQ:BIOL (6/18/2024, 8:15:46 PM)

After market: 0.109 -0.02 (-15.5%)

0.129

-0.02 (-13.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13
Earnings (Next)08-08
Inst Owners0%
Inst Owner Change0%
Ins Owners37.15%
Ins Owner Change0%
Market Cap4.31M
Revenue(TTM)48.83M
Net Income(TTM)-38.26M
Analysts80
Price Target1.99 (1442.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-37.57%
Min EPS beat(2)-107.61%
Max EPS beat(2)32.47%
EPS beat(4)1
Avg EPS beat(4)-58.19%
Min EPS beat(4)-107.61%
Max EPS beat(4)32.47%
EPS beat(8)2
Avg EPS beat(8)-48.85%
EPS beat(12)4
Avg EPS beat(12)-28.48%
EPS beat(16)6
Avg EPS beat(16)-25.48%
Revenue beat(2)0
Avg Revenue beat(2)-1.51%
Min Revenue beat(2)-2.39%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-8.78%
Min Revenue beat(4)-23.29%
Max Revenue beat(4)-0.64%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)7
Avg Revenue beat(12)1.12%
Revenue beat(16)10
Avg Revenue beat(16)3.28%
PT rev (1m)-82.63%
PT rev (3m)-86.55%
EPS NQ rev (1m)-50%
EPS NQ rev (3m)84.04%
EPS NY rev (1m)-37.5%
EPS NY rev (3m)76.15%
Revenue NQ rev (1m)-4.26%
Revenue NQ rev (3m)-8.58%
Revenue NY rev (1m)-1.61%
Revenue NY rev (3m)-4.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 16.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.25
EYN/A
EPS(NY)-0.1
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS1.46
BVpS0.01
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -111.37%
ROE -14222.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.26%
FCFM N/A
ROA(3y)-70.98%
ROA(5y)-70.48%
ROE(3y)-859.83%
ROE(5y)-666.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.89%
GM growth 5Y-1.46%
F-Score3
Asset Turnover1.42
Health
Industry RankSector Rank
Debt/Equity 41.66
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.8%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.64
Altman-Z -13.2
F-Score3
WACC12.07%
ROIC/WACCN/A
Cap/Depr(3y)323.45%
Cap/Depr(5y)202.36%
Cap/Sales(3y)4.06%
Cap/Sales(5y)2.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98%
EPS Next Y98.59%
EPS Next 2Y41.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.13%
Revenue growth 3Y29.23%
Revenue growth 5Y1.27%
Sales Q2Q%-3.21%
Revenue Next Year2.98%
Revenue Next 2Y5.36%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.89%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.18%
OCF growth 3YN/A
OCF growth 5YN/A

BIOLASE INC / BIOL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOLASE INC?

ChartMill assigns a fundamental rating of 1 / 10 to BIOL.


What is the valuation status of BIOLASE INC (BIOL) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOLASE INC (BIOL). This can be considered as Overvalued.


How profitable is BIOLASE INC (BIOL) stock?

BIOLASE INC (BIOL) has a profitability rating of 0 / 10.